

1 **Thromboembolic risk in hospitalised and non-hospitalised Covid-19 patients: A self-**  
2 **controlled case series analysis of a nation-wide cohort**

3

4 Frederick K Ho<sup>1</sup>, Kenneth KS Man<sup>2,3</sup>, Mark Toshner<sup>4</sup>, Colin Church<sup>5</sup>, Carlos Celis-  
5 Morales<sup>6</sup>, Ian CK Wong<sup>2,3</sup>, Colin Berry<sup>6</sup>, Naveed Sattar<sup>6\*</sup>, Jill P Pell<sup>1\*</sup>

6

7 1. Institute of Health and Wellbeing, University of Glasgow

8 2. School of Pharmacy, University College London

9 3. Centre for Safe Medication Practice and Research, Department of Pharmacy  
10 and Pharmacology, University of Hong Kong

11 4. Department of Medicine, School of Clinical Medicine, University of Cambridge

12 5. NHS Greater Glasgow and Clyde

13 6. Institute of Cardiovascular & Medical Sciences, University of Glasgow

14

15 \*Joint senior authors

16

17 Address correspondence to:

18

19 Frederick K Ho, PhD ([Frederick.Ho@glasgow.ac.uk](mailto:Frederick.Ho@glasgow.ac.uk))

20 Institute of Health and Wellbeing

21 University of Glasgow

22 1 Lilybank Gardens

23 Glasgow G12 8RZ

24 United Kingdom

25

26 **Abstract**

27

28 **Objective:** An unexpectedly large number of people infected with Covid-19 had  
29 experienced a thrombotic event. This study aims to assess the associations between  
30 Covid-19 infection and thromboembolism including myocardial infarction (MI),  
31 ischaemic stroke, deep-vein thrombosis (DVT), and pulmonary embolism (PE).

32

33 **Patients and Methods:** A self-controlled case-series study was conducted covering  
34 the whole of Scotland's general population. The study population comprised  
35 individuals with confirmed (positive test) Covid-19 and at least one thromboembolic  
36 event between March 2018 and October 2020. Their incidence rates during the risk  
37 interval (5 days before to 56 days after the positive test) and the control interval (the  
38 remaining periods) were compared intra-personally.

39

40 **Results:** Across Scotland, 1,449 individuals tested positive for Covid-19 and  
41 experienced a thromboembolic event. The risk of thromboembolism was significantly  
42 elevated over the whole risk period but highest in the 7 days following the positive  
43 test (IRR 12.01, 95% CI 9.91-14.56) in all included individuals. The association was  
44 also present in individuals not originally hospitalised for Covid-19 (IRR 4.07, 95% CI  
45 2.83-5.85). Risk of MI, stroke, PE and DVT were all significantly higher in the week  
46 following a positive test. The risk of PE and DVT was particularly high and remained  
47 significantly elevated even 56 days following the test.

48

49 **Conclusion:** Confirmed Covid-19 infection was associated with early elevations in  
50 risk with MI, ischaemic stroke, and substantially stronger and prolonged elevations

51 with DVT and PE both in hospital and community settings. Clinicians should consider  
52 thromboembolism, especially PE, among people with Covid-19 in the community.

53

54 **Keywords:** Covid-19; thromboembolism; stroke

55

## 56 **Introduction**

57

58 Increasing evidence suggests a potential link between Covid-19 infection and  
59 thromboembolism, which could affect a range of organs resulting in: myocardial  
60 infarction (MI), ischaemic stroke, pulmonary embolism (PE), and deep vein  
61 thrombosis (DVT).

62

63 First indications of a potential link came from a case report that described pulmonary  
64 embolism in a patient infected with Covid-19 who had no relevant risk factors or past  
65 medical history.<sup>2</sup> Subsequently hospital-based case series supported the hypothesis,  
66 including ischaemic stroke in five younger (33-49 years) patients who tested positive  
67 for Covid-19.<sup>3</sup> A recent meta-analysis of 3,487 Covid-19 patients from 30 studies  
68 produced a 26% pooled incidence of VTE, but concluded that the existing evidence  
69 was low-quality and heterogeneous.<sup>5</sup> Similar findings were reported by another  
70 meta-analysis focused on PE and DVT.<sup>6</sup> VTE has now been recognised as a  
71 relatively common complication of Covid-19 and clinical guidelines recommend the  
72 use of pharmacological prophylaxis following risk assessment.<sup>7</sup> However, clinical  
73 trials have provided heterogeneous findings, potentially depending on the severity of  
74 Covid-19.<sup>8,9</sup>

75

76 The current evidence, however, is mainly based on crude incidence from  
77 hospitalised case series. Since hospitalised patients are a highly-selected minority of  
78 those infected with Covid-19, these studies are unrepresentative and not  
79 generalisable to the general population.<sup>10</sup> It is unknown whether people who are  
80 asymptomatic or with mild Covid-19 symptoms (non-hospitalised) were also at a

81 higher risk of thromboembolic events. Even in studies comparing thromboembolic  
82 risk between individuals with and without Covid-19<sup>11</sup>, unobserved confounding is still  
83 a major concern. To address these limitations, we conducted a self-controlled case  
84 series study (SCCS) using a national, general population cohort. This method  
85 overcomes bias due to unobserved health conditions. Because SCCS is conducted  
86 only among people with any thromboembolic events, we conducted a  
87 supplementary cohort analysis to verify the findings.

88

89

## 90 **Methods**

91

### 92 *Data sources*

93

94 We undertook individual-level record linkage of five health databases covering the  
95 whole of Scotland (5.5 million population) between March 2018 and October 2020:  
96 The Community Health Index (CHI) register; Electronic Communication of  
97 Surveillance in Scotland (ECOSS); Rapid Preliminary Inpatient Data (RAPID);  
98 Scottish Morbidity Record 01 (SMR01), and death certificates.

99

100 The CHI register provides sociodemographic information (age, sex, area  
101 socioeconomic deprivation). Deprivation is measured using the Scottish Index of  
102 Multiple Deprivation (SIMD), derived from seven domains – income, education,  
103 health, employment, crime, housing, and access to services – and categorised into  
104 general population quintiles. ECOSS collects laboratory data on infectious diseases,  
105 including test date and result. RAPID collects real-time data on hospitalisation,

106 including dates of admission and discharge, and type of ward, and SMR01 records  
107 diseases using International Classification of Diseases (ICD-10) codes and  
108 procedures using Office of Population Censuses and Surveys (OPCS-4) codes.  
109 Death certificates provide the date and cause (using ICD-10) of all deaths, whether  
110 in hospital or the community. The Community Health Index (CHI), a unique identifier,  
111 is used across all databases enabling exact matching. We extracted records  
112 covering 1 March 2018 to 5 October 2020 inclusive for all databases except the  
113 ECOSS Covid-19 test data which covered 1 March 2020 to 5 October 2020. The  
114 Scottish data were accessed through the eDRIS, Public Health Scotland and have  
115 been utilised in several previous epidemiological studies.<sup>12,13</sup> Approval for the study  
116 was provided by the Public Benefit and Privacy Panel for Health and Social Care  
117 (reference 2021-0064).

118

119 In the supplementary cohort analysis, all individuals with a Covid-19 test positive  
120 were included as the exposed group. For each exposed individual, 10 age-, sex-,  
121 and deprivation-matched individuals who did not have a test positive were included  
122 using probability density matching.

123

#### 124 *Outcomes*

125

126 This study included five outcomes ascertained from SMR01 and death certificates:  
127 myocardial infarction (MI; ICD-10: I21), ischaemic stroke (I63-64), pulmonary  
128 embolism (PE; I26), and deep-vein thrombosis (DVT; I80.1-80.9, I82.8, I82.9), as  
129 well as thromboembolism (composite of all four). To test the specificity of any  
130 association between Covid-19 and thromboembolism, we also included a composite

131 negative control outcome of elective surgery for hernia repair (OPCS-4 T19, T21-27),  
132 colonoscopy (OPCS-4 H22, H25, H28), cataract surgery (OPCS-4 C71-75, C77,  
133 C79), or hip/knee replacement (OPCS-4 W37-42, W93-95, O18).

134

### 135 *Statistical Analyses*

136

137 The self-controlled case series (SCCS) method was chosen to analyse the  
138 association between Covid-19 infection and outcomes (Supplementary Figure 1), in  
139 favour of a traditional cohort approach, because of its ability to control for  
140 intrapersonal time-invariant confounders, and the UK's testing strategy. Frail  
141 individuals with long-term conditions were more likely both to be tested and  
142 experience adverse outcomes. These confounders may not be well recorded in the  
143 routine data. With a new condition, such as Covid-19, other unknown confounders  
144 may also exist. The SCCS method eliminates intrapersonal time-invariant  
145 confounders because each person acts as their own control.<sup>14</sup> The method has been  
146 widely-used in epidemiological studies, including influenza and myocardial  
147 infarction.<sup>15</sup>

148

149 The study population comprised everyone in Scotland who had confirmed (positive  
150 real-time PCR test) Covid-19 infection and had experienced one or more  
151 thromboembolic event over the study period. The incidence rate ratio (IRR) of  
152 thromboembolic outcomes was derived from the ratio of incidence rates in risk and  
153 control intervals. The risk interval was defined as between 5 days before and 54  
154 days after the sample was taken for their first positive Covid-19 test. The risk interval  
155 was categorised into: 5 to 1 day before; 0 to 7 days after; 8 to 28 days after; and 29

156 to 56 days after. The five days prior to confirmed infection were included in the risk  
157 period to take account of lags in symptom development and testing. The control  
158 interval was defined as the remaining study period. Because the UK Covid-19  
159 pandemic started in March 2020, the majority of the control interval occurred prior to  
160 infection.

161

162 Conditional Poisson regression was used adjusting for participant age in quintile  
163 groups, the main time-varying confounder. Deriving rates for both the risk and control  
164 intervals from the same individual obviated the need to control statistically for time-  
165 invariant confounders. Because individuals who had fatal events prior to the  
166 pandemic had not had a chance for Covid-19 test, standard SCCS cannot be applied  
167 to fatal events, and the models were run initially for non-fatal hospitalisations. We  
168 then repeated the analyses for the composite outcome of hospitalisation or death  
169 using the extended SCCS for event-dependent observation periods, which was  
170 described elsewhere.<sup>16</sup>

171

172 Subgroup analyses were conducted by Covid-19 admission (those with Covid-19 as  
173 primary diagnosis versus those without), age ( $\leq 75$  versus  $> 75$  years), sex, and  
174 socioeconomic deprivation (SIMD quintile 1-3 versus SIMD quintile 4-5). P-values for  
175 subgroup differences were calculated. Additional subgroup analysis was conducted  
176 for age ( $\leq 65$ , 66-80,  $> 80$  years) to explore any age trends, even though the number  
177 of events were not sufficient to conduct formal tests. Three sensitivity analyses were  
178 conducted. Firstly, seasonality, in three-month categories, were adjusted because  
179 cardiovascular diseases exhibit seasonal patterning. Secondly, we included an  
180 extended risk interval, 14 to 6 days prior to a positive test. If the elevated risk in this



181 extended interval is lower than that in the immediate pre-test interval, reverse  
182 causation is less likely. Thirdly, as Covid-19 infection was not tested prior to the 2020  
183 pandemic, we restricted the analysis to cases with events after 1 February 2020.  
184 Lastly, we calculated the E-values to investigate how robust our findings are  
185 regarding time-varying confounders.<sup>17</sup> A high E-value suggest that only strong time-  
186 varying confounder could nullify the findings.

187

188 A supplementary cohort analysis was conducted. Time-to-event (from test positive in  
189 the exposed individual) to the thromboembolic events was regressed by Covid-19  
190 test positive, controlling for age, sex, and deprivation using Cox proportional hazard  
191 model. Proportional hazard assumptions were checked using the Schoenfeld  
192 residuals. All analyses were conducted in R version 3.5.1 with the packages *SCCS*  
193 and *survival*.

194

## 195 **Results**

196

197 Of the 30,709 individuals who had at least one positive Covid-19 test (Figure 1)  
198 between 1 March 2020 and 5 October 2020, the incidence rates were 44.0, 67.0,  
199 48.6, 18.8 per 1,000 person-years for MI, ischaemic stroke, PE, and DVT  
200 respectively. This SCCS analysis further excluded 29,260 individuals because they  
201 did not have thromboembolic events in the study period. Of the 1,449 individuals  
202 who had thromboembolic events, 117 died out-of-hospital, 81 died in-hospital and  
203 1,251 had non-fatal events. Less than one-third (31.5%) of the individuals had a  
204 Covid-19 primary diagnosis in hospital. Among people with non-fatal events, the  
205 median age were 77 years (interquartile range [IQR] 65-85 years), half were male,

206 and 26.46% lived in the most deprived quintile (Table 1). Median age was older for  
207 ischaemic stroke (82 years) and younger for PE (71 years) and DVT (73 years).  
208 Women accounted for a higher percentage (58.6%) of those with DVT.

209

210 The risk of non-fatal thromboembolism was significantly higher over the whole risk  
211 interval and highest within the seven days following the positive test (IRR 12.01, 95%  
212 CI 9.91-14.56) (Table 2). The associations were strongest for PE followed by DVT  
213 (Figure 2); which had similar risk patterns to overall thromboembolism. The  
214 associations with MI and ischaemic stroke were smaller in magnitude but  
215 nonetheless significant in the 7 days following a positive test, as well as the previous  
216 5 days for MI only. Except for MI, all IRRs in the seven-day post-test interval were  
217 significantly stronger than those in the pre-test intervals ( $P_s < 0.04$ ). As expected,  
218 there was no significant change in the risk of elective surgery before or after a  
219 positive Covid-19 test. The findings for the composite outcome of fatal and non-fatal  
220 thromboembolism were similar to those for non-fatal thromboembolism, after  
221 accounting for censoring.

222

223 Adjusting for seasonality did not alter the findings (Supplementary Table 1). The  
224 extended pre-test risk interval generally had lower IRRs than the immediate pre-test  
225 interval, and were non-significant for MI, ischaemic stroke, and PE. Including only  
226 participants with thromboembolic events after February 2020 resulted in similar IRR  
227 estimates. The E-values ranged from 5.53 (MI) to 40.59 (PE) for the lower bound of  
228 95% CIs within seven days of a positive test (Supplementary Table 2).

229

230 On subgroup analysis, the associations between a test positive and  
231 thromboembolism were significant regardless of Covid-19 admission, even though  
232 the elevation of risk was stronger among those admitted for Covid-19 (Table 3). A  
233 positive Covid-19 test was also associated with higher risk of thromboembolism  
234 regardless of age, but the magnitude of risk was significantly higher ( $P_{\text{interaction}}$   
235  $<0.0001$ ) in people younger than 75 years. Compared with people aged older than  
236 75 years, those younger had 23 and 47 times higher elevated thromboembolism and  
237 PE risk, respectively, within seven days of a positive Covid-19 test (Table 3). There  
238 appears to be a dose-response trend by age even though insufficient sample size  
239 inhibited formal testing (Supplementary Table 2). A positive Covid-19 test was  
240 associated with higher risk of overall thromboembolism, PE and DVT in both women  
241 and men, but the magnitude of risk was higher in men ( $P_{\text{interaction}} <0.006$ ). The  
242 association between a positive Covid-19 test and ischaemic stroke was significant in  
243 men only. There was no consistent evidence of socioeconomic deprivation being an  
244 effect modifier (Supplementary Table 3).

245

246 The findings from cohort analysis were consistent with those from SCCS  
247 (Supplementary Table 4). Individuals who had a Covid-19 infection was at a higher  
248 risk of all of the outcomes, with strongest association with PE (HR 24.04, 95% CI  
249 18.49-31.33), followed by DVT (HR 10.45, 95% CI 7.02-15.56), ischaemic stroke  
250 (HR 4.40, 95% CI 3.44-5.63), and MI (HR 3.31, 95% CI 2.59-4.22).

251

252

253

254 **Discussion**

255

256 In this national, general population study including hospitalised and community-  
257 dwelling individuals, we demonstrated an elevated risk of thromboembolism in  
258 temporal proximity to confirmed Covid-19 infection. In the week following a positive  
259 test, participants were at significantly increased risk of MI, ischaemic stroke, PE and  
260 DVT, with the increased risk of the latter two being marked (Day 0 to +7 IRRs of >27  
261 and >17-fold, respectively) – with risk ratios substantially exceeding those previously  
262 associated with upper respiratory infections<sup>18</sup> – and elevated risk continuing for some  
263 time thereafter. The risk ratios were even higher in younger people and in men. The  
264 clear implication of this work is that PE/DVT risks are substantially elevated in  
265 hospitalised patients as compared to more modest and shorter atherothrombotic  
266 risks. However, there appears a broader thrombotic impact not confined to  
267 hospitalised populations, albeit at a lower risk level.

268

269 It is worth noting that the associations were also significant in individuals not  
270 hospitalised for Covid-19. Although the IRRs were modest compared with the  
271 hospitalised group, the excess risk for PE was sustained at near three-fold for more  
272 than 1-2 months after the initial Covid-19 infection. This modest excess risk may also  
273 be applicable to a large number of people who were infected with Covid-19 but not  
274 hospitalised, which could mean a sizeable population burden. The annual incidence  
275 of PE in the UK general population was 0.98 per 1,000<sup>19</sup>. If the IRR on this study  
276 (3.92 in the first 7 days of non-hospitalised group) is applicable to the general  
277 population, this would translate to a rate difference of 3.84 in 1,000. There were 4.27

278 million people who tested positive for Covid-19 in the UK as of 16 March 2021,  
279 indicating that at least 16,400 new PE cases could have been caused by Covid-19.

280

281 At the present time, unpublished results from ICU Covid-19 populations have led to  
282 early stopping of anticoagulant therapeutic arms because of signals suggestive of  
283 harm.<sup>8</sup> Conversely the same collated international studies have intimated a  
284 significant decreased need for life support and improved results from less severe  
285 hospitalised patients.<sup>9</sup> Such heterogenous results could be related to the severity of  
286 Covid-19, as well as the timing of administering pharmacologic prophylaxis. Given  
287 the potentially treatable nature of thrombotic events, urgent work needs to be  
288 considered in prevention and treatment trial design to consider risk stratification  
289 strategy that includes Covid-19 severity, age, and sex.

290

291 Our new findings are in line but meaningfully extend previous Covid-19 studies,  
292 including another national cohort from Denmark<sup>11</sup>. A meta-analysis of over 100,000  
293 Covid-19 patients reported that 1.2% developed ischaemic stroke;<sup>20</sup> a large  
294 proportion even considering their age and vascular risk profile. A hospital-based  
295 case-control study of 123 patients found an association (odds ratio 3.9) between  
296 Covid-19 infection and acute ischemic stroke, after controlling for age, sex, and  
297 vascular risk factors.<sup>21</sup> Similarly, two meta-analyses reported high rates of PE and  
298 DVT in patients with Covid-19.<sup>5,6</sup> Of note, traditional thromboembolic risk factors  
299 were not significantly associated with PE in Covid-19 patients suggesting the  
300 pathways may be different.<sup>22</sup> It should also be noted that previous studies<sup>23</sup> have  
301 shown that the PE found in severe Covid-19 patients might actually be primarily

302 caused by pulmonary thrombi rather than pulmonary emboli, which warrants further  
303 investigation.

304

305 This study's association pattern for MI is similar to that for influenza, with 5-6 times  
306 higher risk in the first 7 days after a test positive.<sup>15</sup> However, the association of  
307 Covid-19 with VTE appeared to be much stronger than that of other infections. For  
308 example, a study using the same SCCS method found the elevated risk of DVT was  
309 much lower (IRR 1.91 in the first 2 weeks) for upper respiratory infections.<sup>18</sup> The  
310 same study also found that the risk of PE elevated (IRR 2.11 in the first 4 weeks)  
311 following urinary tract infection. These suggest that Covid-19 may have either  
312 different mechanisms, or a stronger systemic inflammation (in keeping with the  
313 cytokine storm), leading to an exponential difference in the risk of PE/DVT compared  
314 to other infections, while having similar elevation in MI risk.

315

316 Our study demonstrated that the association with ischaemic stroke was significantly  
317 stronger in younger ( $\leq 75$  years) individuals. This is consistent with previous reports  
318 of relatively young people (mean age 53-60 years) with Covid-19 requiring  
319 thrombectomy.<sup>24-26</sup> In addition, among stroke patients, those who tested positive for  
320 Covid-19 were on average 7-15 years younger than those tested negative.<sup>27,28</sup> The  
321 underlying mechanism warrants further investigation but could relate to cytokine  
322 storm, at least in some people.<sup>29</sup> Historical reports showed healthy young people  
323 were more likely to experience cytokine storm following viral infections,<sup>29</sup> and  
324 cytokine storm in Covid-19 patients leading to hypercoagulable was a hypothesised  
325 mechanism for thromboembolism.<sup>30</sup> The finding that Covid-19 is associated with a  
326 higher risk of thromboembolism in men than women may partially explain our

327 previous finding that men have worse case-fatality following Covid-19 infection.<sup>31</sup>

328 This hypothesis requires further study.

329

330 Our study has several strengths. Firstly, it was unselective; covering the whole of  
331 Scotland and all confirmed Covid-19 cases regardless of whether they were  
332 hospitalised. This avoided the selection bias intrinsic to hospital-based studies. Since  
333 both Covid-19 infection and thromboembolism increase the chance of hospitalisation,  
334 selecting only hospital cases inevitably results in collider bias.<sup>10</sup> Secondly, time-  
335 invariant confounders, including unknown and unmeasured confounders, were  
336 perfectly controlled by using participants as their own controls., The key time-varying  
337 confounders, age and seasonality, were adjusted for in the model.<sup>14</sup> The use of E-  
338 values showed that the elevated risk within seven days of test positive would only be  
339 meaningfully nullified if there were very strong time-varying confounders that could  
340 increase/decrease the risk of test positive and thromboembolic events by 5 to 20  
341 times. Thirdly, we were able to separately analyse non-fatal events, using the  
342 standard SCCS method, and all events, using a specific method designed for  
343 censored data,<sup>16</sup> and the two approaches produced consistent findings. This, along  
344 with the sensitivity analysis including only events shortly before the Covid-19  
345 pandemic, suggest the results should be robust against immortal time biases.

346

347 However, the findings of this study are still subject to the following limitations. To  
348 ensure internal validity, this study opted for the SCCS method, which only included  
349 patients with at least one thromboembolism during the study period. This may limit  
350 the generalisability of the findings to people with lower risk of these events even  
351 though our confirmatory cohort analysis showed similar results. It should be noted

352 that, if the elevated risk of PE is truly causal, the estimates that we provided could be  
353 an underestimate. The IRR for the latest categories in the risk interval was still  
354 significantly greater than one, suggesting a long tail of risk elevation and thus some  
355 of the pre- and post-infection control interval could be misspecified. Patients with no  
356 or mild symptoms from Covid-19 infection are less likely to have been tested,  
357 especially at the beginning of the pandemic when testing capacity was lower. The  
358 increased risk of thromboembolism demonstrated in the days prior to confirmed  
359 infection is likely to reflect the time lag between actual date of infection and our proxy  
360 measure of it; date of specimen collection. Reverse causation is possible in some  
361 patients; for example, nosocomial infection of patients hospitalised for  
362 thromboembolic events. However, the lack of an association with elective surgery  
363 suggests that any reverse causation is unlikely to fully explain our findings. The  
364 lowered risk in extended pre-test interval for outcomes except MI also does not  
365 support strong reverse causation. It is highly likely that there was underreporting of  
366 events from the first wave. There were 1465 individuals who died of suspected  
367 Covid-19 (ICD-10: U07.2) without any tests suggesting individuals who had Covid-19  
368 but untested is only a small proportion (4.8%) compared to those tested and unlikely  
369 to change our conclusion. Even though there was no role for routine CT scanning in  
370 Covid-19<sup>32</sup> and data on rates of advanced imaging are not yet clear, it is our  
371 expectation that more extensive imaging in subsequent waves is highly likely to  
372 increase pick-up of thrombus.

373

374 In conclusion, Covid-19 infection was associated with substantially elevated risk of  
375 PE and DVT, with excess PE risk lasting at least 8 weeks post-infection. These  
376 complications should be addressed through prophylaxis and early detection;



377 clinicians should be alerted to the possibility of PEs in community treated patients  
378 with residual or prolonged symptoms. Clinical trials to prevent thrombotic events  
379 should consider the post-hospital convalescent stage where we have demonstrated  
380 ongoing increased risk in addition to younger individuals with Covid-19.

381

## 382 **Acknowledgements**

383

384 This study was supported by the Wellcome Trust ISSF COVID Response Fund in the  
385 University of Glasgow. The authors would like to acknowledge the support of the  
386 eDRIS Team (Public Health Scotland), especially Ms Johanna Bruce, for their  
387 involvement in obtaining approvals, provisioning and linking data and the use of the  
388 secure analytical platform within the National Safe Haven.

389

390

## 391 **References**

- 392 1. Johns Hopkins University & Medicine. Coronavirus Resource Center.  
393 <https://coronavirus.jhu.edu/>. Published 2021. Accessed.
- 394 2. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and  
395 COVID-19 pneumonia: a random association? *European heart journal*.  
396 2020;41(19):1858-1858.
- 397 3. Oxley TJ, Mocco J, Majidi S, et al. Large-vessel stroke as a presenting feature  
398 of Covid-19 in the young. *New England Journal of Medicine*.  
399 2020;382(20):e60.
- 400 4. Klok F, Kruip M, Van der Meer N, et al. Incidence of thrombotic complications  
401 in critically ill ICU patients with COVID-19. *Thrombosis research*. 2020.
- 402 5. Porfidia A, Valeriani E, Pola R, Porreca E, Rutjes AW, Di Nisio M. Venous  
403 thromboembolism in patients with COVID-19: Systematic review and meta-  
404 analysis. *Thrombosis research*. 2020;196:67-74.
- 405 6. Suh YJ, Hong H, Ohana M, et al. Pulmonary Embolism and Deep Vein  
406 Thrombosis in COVID-19: A Systematic Review and Meta-Analysis.  
407 *Radiology*. 2020:203557.
- 408 7. NICE. COVID-19 rapid guideline: reducing the risk of venous  
409 thromboembolism in over 16s with COVID-19. NICE guideline [NG186] Web  
410 site. <https://www.nice.org.uk/guidance/ng186>. Published 2020. Accessed 13  
411 January, 2021.
- 412 8. Statement from the REMAP-CAP trial on blood thinners in COVID-19 patients  
413 [press release]. 2020.
- 414 9. Full-dose blood thinners decreased need for life support and improved  
415 outcome in hospitalized COVID-19 patients [press release]. 2021.
- 416 10. Griffith G, Morris TT, Tudball M, et al. Collider bias undermines our  
417 understanding of COVID-19 disease risk and severity. *Nature Communication*  
418 2020;11(5749).
- 419 11. Dalager-Pedersen M, Lund LC, Mariager T, et al. Venous thromboembolism  
420 and major bleeding in patients with COVID-19: A nationwide population-based

- 421 cohort study. *Clinical infectious diseases: an official publication of the*  
422 *Infectious Diseases Society of America*. 2021.
- 423 12. Mackay DF, Nelson SM, Haw SJ, Pell JP. Impact of Scotland's smoke-free  
424 legislation on pregnancy complications: retrospective cohort study. *PLoS Med*.  
425 2012;9(3):e1001175.
- 426 13. Turner S, Mackay D, Dick S, Semple S, Pell JP. Associations between a  
427 smoke-free homes intervention and childhood admissions to hospital in  
428 Scotland: an interrupted time-series analysis of whole-population data. *The*  
429 *Lancet Public Health*. 2020;5(9):e493-e500.
- 430 14. Whitaker HJ, Paddy Farrington C, Spiessens B, Musonda P. Tutorial in  
431 biostatistics: the self-controlled case series method. *Statistics in medicine*.  
432 2006;25(10):1768-1797.
- 433 15. Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction  
434 after laboratory-confirmed influenza infection. *New England Journal of*  
435 *Medicine*. 2018;378(4):345-353.
- 436 16. Farrington CP, Whitaker HJ, Hocine MN. Case series analysis for censored,  
437 perturbed, or curtailed post-event exposures. *Biostatistics*. 2009;10(1):3-16.
- 438 17. Haneuse S, VanderWeele TJ, Arterburn D. Using the E-value to assess the  
439 potential effect of unmeasured confounding in observational studies. *JAMA*.  
440 2019;321(6):602-603.
- 441 18. Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep  
442 vein thrombosis and pulmonary embolism after acute infection in a community  
443 setting. *The Lancet*. 2006;367(9516):1075-1079.
- 444 19. Kempny A, McCabe C, Dimopoulos K, et al. Incidence, mortality and bleeding  
445 rates associated with pulmonary embolism in England between 1997 and  
446 2015. *International journal of cardiology*. 2019;277:229-234.
- 447 20. Nannoni S, de Groot R, Bell S, Markus HS. Stroke in COVID-19: a systematic  
448 review and meta-analysis. *International Journal of Stroke*.  
449 2020:1747493020972922.
- 450 21. Belani P, Schefflein J, Kihira S, et al. COVID-19 is an independent risk factor  
451 for acute ischemic stroke. *American Journal of Neuroradiology*.  
452 2020;41(8):1361-1364.
- 453 22. Fauvel C, Weizman O, Trimaille A, et al. Pulmonary embolism in COVID-19  
454 patients: a French multicentre cohort study. *European heart journal*.  
455 2020;41(32):3058-3068.
- 456 23. Cattaneo M, Bertinato EM, Bircocchi S, et al. Pulmonary embolism or  
457 pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose  
458 heparin for thromboprophylaxis justified? 2020.
- 459 24. Wang A, Mandigo GK, Yim PD, Meyers PM, Lavine SD. Stroke and  
460 mechanical thrombectomy in patients with COVID-19: technical observations  
461 and patient characteristics. *Journal of NeuroInterventional Surgery*.  
462 2020;12(7):648-653.
- 463 25. Sweid A, Hammoud B, Bekelis K, et al. Cerebral ischemic and hemorrhagic  
464 complications of coronavirus disease 2019. *International Journal of Stroke*.  
465 2020;15(7):733.
- 466 26. Escalard S, Maïer B, Redjem H, et al. Treatment of Acute Ischemic Stroke  
467 due to Large Vessel Occlusion With COVID-19: Experience From Paris.  
468 *Stroke*. 2020:STROKEAHA. 120.030574.
- 469 27. Yaghi S, Ishida K, Torres J, et al. SARS2-CoV-2 and stroke in a New York  
470 healthcare system. *Stroke*. 2020:STROKEAHA. 120.030335.

- 471 28. Majidi S, Fifi JT, Ladner TR, et al. Emergent large vessel occlusion stroke  
472 during New York City's COVID-19 outbreak: clinical characteristics and  
473 paraclinical findings. *Stroke*. 2020;51(9):2656-2663.
- 474 29. Ma J, Dushoff J, Earn DJ. Age-specific mortality risk from pandemic influenza.  
475 *Journal of theoretical biology*. 2011;288:29-34.
- 476 30. Ellul M, Benjamin L, Singh B, et al. Neurological Associations of COVID-19.  
477 *The Lancet Neurology*. 2020;19(9):767-783.
- 478 31. Jani BD, Ho FK, Lowe DJ, et al. Comparison of COVID-19 outcomes among  
479 shielded and non-shielded populations: A general population cohort study of  
480 1.3 million. *medRxiv*. 2020.
- 481 32. The role of CT in patients suspected with COVID-19 infection [press release].  
482 2020.  
483

**Figure 1.** Participant flowchart

**Figure 2.** Associations between Covid-19 and non-fatal outcomes.

IRR shown is the within incidence rate ratio for outcomes. Incidence rates in the risk period (5 days prior to 56 after a positive Covid-19 test) were compared against the control period (all remaining time in study period) for each person.

**Table 1.** Patients characteristics for analysis of non-fatal admissions.

	<b>Composite</b>	<b>Myocardial infarction</b>	<b>Ischaemic stroke</b>	<b>Pulmonary embolism</b>	<b>Deep-vein thrombosis</b>	<b>Elective surgery*</b>
N for all events	1449	376	560	417	179	123
N for admissions only	1332	337	505	391	174	123
N for non-fatal admissions only	1251	319	473	359	169	116
Covid-19 as primary diagnosis in admission episode	389 (31.5)	104 (32.6)	123 (26.0)	145 (40.4)	41 (26.6)	14 (12.1)
Median (IQR) age, years	77 (65-85)	78 (67-85)	82 (73-87)	71 (59-81)	73 (59-82)	78 (70-85)
Sex						
Female	626 (50.04)	128 (40.13)	246 (52.01)	180 (50.14)	99 (58.58)	45 (38.79)
Male	625 (49.96)	191 (59.87)	227 (47.99)	179 (49.86)	70 (41.42)	71 (61.21)
SIMD quintile						
1 <sup>st</sup> (Most deprived)	331 (26.46)	91 (28.53)	124 (26.22)	84 (23.40)	47 (27.81)	34 (29.31)
2 <sup>nd</sup>	282 (22.54)	79 (24.76)	100 (21.14)	88 (24.51)	32 (18.93)	21 (18.10)
3 <sup>rd</sup>	230 (18.39)	55 (17.24)	94 (19.87)	65 (18.11)	33 (19.53)	21 (18.10)
4 <sup>th</sup>	230 (18.39)	53 (16.61)	95 (20.08)	68 (18.94)	27 (15.98)	25 (21.55)
5 <sup>th</sup> (Least deprived)	178 (14.23)	41 (12.85)	60 (12.68)	54 (15.04)	30 (17.75)	15 (12.93)

Numbers (%) are presented unless otherwise specified.

\*Elective surgery included hernia repair, colonoscopy, cataract surgery, and hip and knee replacement, and is a negative control outcome

**Table 2.** Associations between COVID-19 and outcomes.

Outcome by risk intervals	Non-fatal events		All events <sup>†</sup>	
	IRR (95% CI)	P	IRR (95% CI)	P
<b>Composite</b>				
5-1 days before	<b>4.77 (3.20, 7.10)</b>	<b>&lt;0.0001</b>	<b>3.71 (2.50, 5.49)</b>	<b>&lt;0.0001</b>
0-7 days after	<b>12.01 (9.91, 14.56)</b>	<b>&lt;0.0001</b>	<b>5.70 (4.72, 6.89)</b>	<b>&lt;0.0001</b>
8-28 days after	<b>2.82 (2.16, 3.67)</b>	<b>&lt;0.0001</b>	<b>1.54 (1.22, 1.94)</b>	<b>0.0003</b>
28-56 days after	<b>2.30 (1.77, 3.00)</b>	<b>&lt;0.0001</b>	<b>1.51 (1.21, 1.88)</b>	<b>0.0002</b>
<b>Myocardial infarction</b>				
5-1 days before	<b>5.15 (2.54, 10.46)</b>	<b>&lt;0.0001</b>	<b>3.79 (1.86, 7.71)</b>	<b>0.0002</b>
0-7 days after	<b>5.16 (3.04, 8.73)</b>	<b>&lt;0.0001</b>	<b>1.98 (1.23, 3.18)</b>	<b>0.005</b>
8-28 days after	1.51 (0.77, 2.95)	0.23	0.85 (0.50, 1.44)	0.55
28-56 days after	1.15 (0.56, 2.35)	0.70	0.90 (0.53, 1.50)	0.67
<b>Ischaemic stroke</b>				
5-1 days before	2.12 (0.88, 5.13)	0.10	1.58 (0.65, 3.84)	0.31
0-7 days after	<b>7.22 (5.02, 10.38)</b>	<b>&lt;0.0001</b>	<b>3.25 (2.34, 4.50)</b>	<b>&lt;0.0001</b>
8-28 days after	0.75 (0.35, 1.58)	0.45	0.69 (0.42, 1.12)	0.14
28-56 days after	1.11 (0.63, 1.94)	0.72	0.94 (0.63, 1.41)	0.77
<b>Pulmonary embolism</b>				
5-1 days before	<b>9.95 (5.42, 18.27)</b>	<b>&lt;0.0001</b>	<b>7.47 (4.13, 13.51)</b>	<b>&lt;0.0001</b>
0-7 days after	<b>27.55 (20.55, 36.95)</b>	<b>&lt;0.0001</b>	<b>16.81 (12.46, 22.69)</b>	<b>&lt;0.0001</b>
8-28 days after	<b>7.27 (5.07, 10.43)</b>	<b>&lt;0.0001</b>	<b>4.52 (3.21, 6.35)</b>	<b>&lt;0.0001</b>
28-56 days after	<b>5.59 (3.87, 8.07)</b>	<b>&lt;0.0001</b>	<b>3.54 (2.54, 4.93)</b>	<b>&lt;0.0001</b>
<b>Deep vein thrombosis</b>				
5-1 days before	<b>4.67 (1.48, 14.72)</b>	<b>0.008</b>	<b>4.23 (1.34, 13.32)</b>	<b>0.01</b>
0-7 days after	<b>17.44 (11.00, 27.66)</b>	<b>&lt;0.0001</b>	<b>11.51 (7.30, 18.16)</b>	<b>&lt;0.0001</b>
8-28 days after	<b>3.64 (1.90, 7.01)</b>	<b>0.0001</b>	<b>2.43 (1.27, 4.67)</b>	<b>0.008</b>
28-56 days after	1.98 (0.91, 4.29)	0.08	1.77 (0.92, 3.42)	0.09
<b>Elective surgeries*</b>				
5-1 days before	-	-	-	-
0-7 days after	1.69 (0.41, 6.88)	0.47	1.28 (0.40, 4.06)	0.67
8-28 days after	1.78 (0.65, 4.90)	0.26	0.94 (0.34, 2.59)	0.91
28-56 days after	2.28 (0.98, 5.32)	0.06	1.19 (0.51, 2.76)	0.68

Patients' age quintile was adjusted

IRR: incidence rate ratio


\*Elective surgery included hernia repair, colonoscopy, cataract surgery, and hip/knee replacement, and is a negative control outcome

<sup>†</sup>Including both fatal and non-fatal events, with event dependent observation handled using specialised method

**Table 3.** Subgroup analysis for non-fatal events.

Outcome by risk intervals	Covid-19 hospitalisation			Age			Sex		
	Yes IRR (95% CI)	No IRR (95% CI)	P <sub>interaction</sub>	≤75 years IRR (95% CI)	>75 years IRR (95% CI)	P <sub>interaction</sub>	Female IRR (95% CI)	Male IRR (95% CI)	P <sub>interaction</sub>
<b>Composite</b>									
5-1 days before	<b>12.45 (7.37, 21.03)</b>	<b>2.48 (1.33, 4.63)</b>	<b>0.0001</b>	3.80 (2.44, 5.93)	2.60 (1.81, 3.72)	0.19	<b>2.22 (1.41, 3.47)</b>	<b>4.31 (3.02, 6.15)</b>	<b>0.03</b>
0-7 days after	<b>36.97 (28.69, 47.64)</b>	<b>4.07 (2.83, 5.85)</b>	<b>&lt;0.0001</b>	<b>22.78 (17.58, 29.53)</b>	<b>5.94 (4.35, 8.12)</b>	<b>&lt;0.0001</b>	<b>6.36 (4.47, 9.04)</b>	<b>19.44 (15.38, 24.58)</b>	<b>&lt;0.0001</b>
8-28 days after	<b>6.16 (4.18, 9.09)</b>	<b>1.82 (1.26, 2.63)</b>	<b>&lt;0.0001</b>	<b>5.79 (4.16, 8.07)</b>	<b>1.24 (0.78, 1.97)</b>	<b>&lt;0.0001</b>	2.64 (1.83, 3.82)	3.19 (2.18, 4.66)	0.50
28-56 days after	<b>4.85 (3.27, 7.20)</b>	<b>1.50 (1.04, 2.17)</b>	<b>&lt;0.0001</b>	<b>4.27 (3.03, 6.03)</b>	<b>1.12 (0.72, 1.74)</b>	<b>&lt;0.0001</b>	2.28 (1.59, 3.27)	2.46 (1.66, 3.65)	0.79
<b>Myocardial infarction</b>									
5-1 days before	3.58 (0.86, 14.88)	6.17 (2.73, 13.95)	0.52	4.14 (2.00, 8.54)	3.36 (1.80, 6.26)	0.67	4.29 (2.15, 8.58)	3.47 (1.82, 6.60)	0.66
0-7 days after	8.09 (3.87, 16.90)	3.38 (1.50, 7.65)	0.12	6.19 (2.85, 13.42)	3.65 (1.69, 7.88)	0.34	3.35 (1.22, 9.18)	6.45 (3.46, 12.00)	0.28
8-28 days after	1.00 (0.24, 4.17)	1.85 (0.86, 3.96)	0.46	2.49 (1.08, 5.77)	0.77 (0.24, 2.45)	0.11	1.58 (0.57, 4.39)	1.43 (0.58, 3.50)	0.89
28-56 days after	1.28 (0.39, 4.22)	1.15 (0.47, 2.81)	0.89	1.01 (0.32, 3.23)	0.97 (0.35, 2.64)	0.96	1.41 (0.51, 3.92)	0.94 (0.34, 2.57)	0.60
<b>Ischaemic stroke</b>									
5-1 days before	3.23 (0.79, 13.30)	1.62 (0.52, 5.06)	0.45	1.70 (0.54, 5.39)	1.84 (1.00, 3.37)	1.00	1.21 (0.50, 2.96)	2.58 (1.32, 5.08)	0.18
0-7 days after	<b>14.03 (8.11, 24.27)</b>	<b>4.22 (2.50, 7.12)</b>	<b>0.0019</b>	<b>17.81 (10.67, 29.72)</b>	<b>3.63 (2.07, 6.38)</b>	<b>&lt;0.0001</b>	<b>2.05 (0.84, 5.00)</b>	<b>13.27 (8.79, 20.04)</b>	<b>0.0001</b>
8-28 days after	1.26 (0.39, 4.07)	0.51 (0.19, 1.37)	0.25	0.45 (0.06, 3.27)	0.81 (0.36, 1.84)	1.00	0.75 (0.28, 2.03)	0.72 (0.23, 2.26)	0.96
28-56 days after	2.37 (1.06, 5.29)	0.60 (0.27, 1.36)	0.02	1.46 (0.53, 4.02)	0.93 (0.47, 1.83)	0.47	1.20 (0.59, 2.45)	0.96 (0.39, 2.37)	0.75
<b>Pulmonary embolism</b>									
5-1 days before	<b>50.25 (24.26, 104.07)</b>	<b>2.09 (0.52, 8.44)</b>	<b>0.0001</b>	5.36 (2.60, 11.08)	3.40 (1.64, 7.03)	0.39	<b>1.98 (0.73, 5.37)</b>	<b>8.10 (4.42, 14.86)</b>	<b>0.02</b>
0-7 days after	<b>135.97 (88.89, 207.98)</b>	<b>3.92 (1.83, 8.40)</b>	<b>&lt;0.0001</b>	<b>46.84 (32.21, 68.12)</b>	<b>10.36 (5.99, 17.91)</b>	<b>&lt;0.0001</b>	<b>15.22 (9.30, 24.90)</b>	<b>43.82 (29.78, 64.48)</b>	<b>0.0001</b>
8-28 days after	<b>23.97 (14.03, 40.97)</b>	<b>3.54 (2.03, 6.16)</b>	<b>&lt;0.0001</b>	<b>12.64 (8.20, 19.49)</b>	<b>2.04 (0.93, 4.48)</b>	<b>0.0001</b>	5.77 (3.42, 9.71)	9.35 (5.63, 15.54)	0.20
28-56 days after	<b>16.26 (9.35, 28.27)</b>	<b>2.99 (1.74, 5.15)</b>	<b>&lt;0.0001</b>	<b>8.13 (5.16, 12.81)</b>	<b>1.88 (0.90, 3.94)</b>	<b>0.0009</b>	4.98 (3.02, 8.21)	6.21 (3.58, 10.77)	0.57
<b>Deep vein thrombosis</b>									
5-1 days before	<b>24.07 (5.54, 104.49)</b>	<b>1.82 (0.25, 13.20)</b>	<b>0.04</b>	2.20 (0.54, 9.04)	3.83 (1.51, 9.69)	1.00	3.18 (1.16, 8.73)	3.90 (1.20, 12.65)	0.80
0-7 days after	<b>92.44 (46.02, 185.68)</b>	<b>3.77 (1.36, 10.46)</b>	<b>&lt;0.0001</b>	24.21 (13.13, 44.64)	10.59 (5.11, 21.97)	0.09	<b>8.04 (3.49, 18.57)</b>	<b>33.91 (18.80, 61.18)</b>	<b>0.0001</b>
8-28 days after	9.54 (3.15, 28.93)	2.75 (1.18, 6.40)	0.08	5.30 (2.38, 11.80)	1.74 (0.53, 5.68)	0.13	4.89 (2.33, 10.26)	2.03 (0.49, 8.45)	0.33
28-56 days after	1.46 (0.19, 11.55)	2.35 (1.01, 5.46)	0.67	2.85 (1.11, 7.28)	0.91 (0.22, 3.82)	0.19	1.41 (0.44, 4.50)	3.49 (1.23, 9.90)	0.26

Patients' age quintile was adjusted  
IRR: incidence rate ratio; SIMD: Scottish Index of Multiple Deprivation





IRR (95% CI)

**Myocardial infarction**



**Ischaemic stroke**



**Pulmonary embolism**



**Deep-vein thrombosis**



1 5 10 15 20 25 30 35 40

IRR (95% CI)